Free Trial

Barclays PLC Sells 124,824 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

EyePoint Pharmaceuticals logo with Medical background

Barclays PLC lessened its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 50.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 120,221 shares of the company's stock after selling 124,824 shares during the period. Barclays PLC owned approximately 0.18% of EyePoint Pharmaceuticals worth $895,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its position in shares of EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after buying an additional 362,399 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of EyePoint Pharmaceuticals by 1,171.3% during the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock valued at $2,970,000 after buying an additional 342,516 shares during the last quarter. Cyndeo Wealth Partners LLC boosted its position in shares of EyePoint Pharmaceuticals by 35.5% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company's stock valued at $127,000 after buying an additional 4,450 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of EyePoint Pharmaceuticals by 40.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company's stock valued at $108,000 after buying an additional 4,179 shares during the last quarter. Finally, abrdn plc purchased a new position in shares of EyePoint Pharmaceuticals during the fourth quarter valued at approximately $1,719,000. Institutional investors and hedge funds own 99.41% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, Chardan Capital lowered their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, EyePoint Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.29.

Get Our Latest Report on EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Price Performance

EYPT stock traded down $0.29 on Friday, reaching $5.81. 479,431 shares of the company traded hands, compared to its average volume of 824,374. EyePoint Pharmaceuticals, Inc. has a one year low of $3.91 and a one year high of $13.99. The company has a market cap of $399.79 million, a P/E ratio of -2.91 and a beta of 1.58. The firm has a fifty day simple moving average of $6.02 and a 200-day simple moving average of $7.49.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. On average, sell-side analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

EyePoint Pharmaceuticals Profile

(Free Report)

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Recommended Stories

Institutional Ownership by Quarter for EyePoint Pharmaceuticals (NASDAQ:EYPT)

Should You Invest $1,000 in EyePoint Pharmaceuticals Right Now?

Before you consider EyePoint Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.

While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines